Premium
Sequence and structural analysis of the presumed downstream promoter of the canine mdr 1 gene
Author(s) -
Mealey K. L.,
Bentjen S. A.
Publication year - 2003
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1046/j.1476-5829.2003.00002.x
Subject(s) - multiple drug resistance , gene , biology , p glycoprotein , gene expression , promoter , cancer research , homology (biology) , drug resistance , regulation of gene expression , microbiology and biotechnology , genetics
The product of the canine mdr 1 gene, P‐glycoprotein (P‐gp), plays an important role in chemotherapeutic drug resistance of several canine tumours. Increased expression of P‐gp by tumour cells is associated with the multidrug‐resistant phenotype. Because of its importance in cancer chemotherapy, a great deal is known about the regulation of mdr 1 gene expression in human cancer patients and rodent cancer models. In contrast, there is no information regarding the regulation of P‐gp expression in dogs. Initial information regarding the regulation of mdr 1 gene expression can be gained by evaluating the mdr 1 promoter. The downstream promoter of the canine mdr 1 gene was sequenced. Several regulatory elements were identified, including an AP‐1 site, AP‐2 site and SP‐1 site. The presumed canine mdr 1 promoter was similar to that of other species; however, low overall sequence homology may suggest that aspects of P‐gp regulation are distinctive in dogs.